elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
DOTA
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
DOTA
RIS
0.003
(Research Intensity Score)
Papers
476
Top papers
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 · 339 citations
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
2023 · 281 citations
Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
2023 · 108 citations
Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
2021 · 169 citations
FAP-targeted radioligand therapy with 68 Ga/ 177 Lu-DOTA-2P(FAPI) 2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy
2025 · 29 citations
Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68 Ga-Labeled FAPI Dimer
2021 · 163 citations
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum
2024 · 43 citations
First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2
2021 · 132 citations
Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study
2025 · 19 citations
Newest papers
Radiolabelled FAPI Radiotracers in Oncology: A Comprehensive Review of Current Diagnostic and Emerging Therapeutic Applications
2026 · 4 citations
Stable Chelation of Zr-89 and Ac-225 with Dual Size-Selective Macrocyclic py 2 -macrodipa for 225 Ac/ 89 Zr Paired Theranostics
2026
Development of an Optimized CXCR4-Targeting Theranostic Pair
2026 · 1 citations
Radiolabeling efficiency of FENTA chelators and stability of their terbium-161, lutetium-177 and bismuth-213 complexes
2026
Radiolabeling efficiency of FENTA chelators and stability of their terbium-161, lutetium-177 and bismuth-213 complexes
2026
Radiolabeling efficiency of FENTA chelators and stability of their terbium-161, lutetium-177 and bismuth-213 complexes
2026
Abstract 7202: Comparative evaluation of 225Ac-PSMA-Trillium with other 225Ac-PSMA-SMOL assets in a preclinical prostate cancer xenograft model
2026
SPECT Imaging with Bifunctional Technetium-99m Nitrido Bis(thiosemicarbazonato) Complexes Tethered to Inhibitors of the Prostate-Specific Membrane Antigen
2026
High-yield reactor production of terbium-161 using thin-layer gadolinium-160 targets, simplified chloride based separation and radiolabeling of DOTA based ligands
2026
Browse all papers →
DOTA's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
DOTA's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link